Non-small cell lung cancer
Conditions
Interventions
STAS-positive group:None
STAS-negative group:None
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age range from 18 to 90 years old, gender not specified. 2. Preoperative assessment confirms resectable lesions. 3. Underwent robot-assisted, thoracoscopic, or traditional open-chest lung surgery, with pathology confirming NSCLC. 4. ECOG performance status score of 0-1. 5. Good organ function. 6. Willing and able to comply with the study protocol's visits, treatment schedules, laboratory tests, and other research procedures.
Exclusion criteria
Exclusion criteria: 1. Pathology includes malignant tumors or benign lesions of other types or undetermined types; 2. Patients with clinical or pathological stage IV; 3. Uncertain whether STAS (Spread Through Air Spaces) has occurred; 4. Patients who have not undergone tumor molecular pathology and PD-L1 expression testing; 5. Patients who have received any preoperative induction therapy; 6. Known history of active tuberculosis; 7. Known active infection requiring systemic treatment; 8. Patients with any known or suspected autoimmune disease or immune deficiency, except: patients with a history of hypothyroidism, if no hormone therapy is needed or if receiving physiological dose hormone replacement therapy; patients with stable type I diabetes with controlled blood glucose levels; 9. Uncontrolled active hepatitis B (defined as a positive hepatitis B surface antigen [HBsAg] test result at the screening period with HBV-DNA levels above the upper limit of normal for the study center’s laboratory); 10. (Patients with HBV-DNA levels < 500 IU/mL who have received at least 14 days of standard local antiviral therapy and are willing to continue antiviral therapy during the study period can be enrolled); active hepatitis C (defined as a positive hepatitis C surface antibody [HCsAb] test result at the screening period, HCV-RNA positive); 11. Known human immunodeficiency virus (HIV) infection (known HIV antibody positive); 12. Vaccination with a live vaccine within 30 days before surgery. This includes, but is not limited to: mumps, rubella, measles, varicella/zoster (chickenpox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine (inactivated virus vaccines are permitted); 13. Known severe or uncontrolled underlying diseases; including but not limited to hemodynamically unstable cardiovascular events within the past 6 months, symptomatic cerebrovascular events, cirrhosis with Child-Pugh grade above A; 14. According to the investigator’s judgment, patients with any disease, treatment, or laboratory abnormality that may confuse the study results or are not in the best interest of the patient to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PD-L1 Expression in Tumor Cells;Proportion of High-Risk Pathological Factors in Tumors (Solid and Micropapillary Components); | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor Pleural Invasion (PL0/PL1/PL2);Tumor Driver Gene Mutations (EGFR, ALK, KRAS); | — |
Countries
China
Contacts
Public ContactQINGQUAN LUO
Shanghai Chest Hospital
Outcome results
None listed